{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:30:57Z","timestamp":1794047457213,"version":"4.8.0"},"reference-count":16,"publisher":"Ferrata Storti Foundation (Haematologica)","issue":"4","license":[{"start":{"date-parts":[[2023,11,30]],"date-time":"2023-11-30T00:00:00Z","timestamp":1701302400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["haematol"],"DOI":"10.3324\/haematol.2023.283884","type":"journal-article","created":{"date-parts":[[2023,11,30]],"date-time":"2023-11-30T03:40:19Z","timestamp":1701315619000},"page":"1279-1284","source":"Crossref","is-referenced-by-count":0,"title":["Comorbidity indices for prognostic evaluation in multiple myeloma: a comprehensive evaluation of the Revised Myeloma Comorbidity Index and other comorbidity indices with pro- and retrospective applications"],"prefix":"10.3324","volume":"109","author":[{"given":"Katja","family":"Schoeller","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriele","family":"Ihorst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heike","family":"Reinhardt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maximilian","family":"Holler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophia","family":"Scheubeck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georg","family":"Herget","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralph","family":"W\u00e4sch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monika","family":"Engelhardt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1856","published-online":{"date-parts":[[2023,11,30]]},"reference":[{"key":"59973","doi-asserted-by":"crossref","unstructured":"Larocca A, Dold SM, Zweegman S. Patient-centered practice in elderly myeloma patients: an overview and consensus from the European Myeloma Network (EMN). Leukemia. 2018; 32(8):1697-1712.","DOI":"10.1038\/s41375-018-0142-9"},{"key":"59974","doi-asserted-by":"crossref","unstructured":"Coulson AB, Royle K-L, Pawlyn C. Frailty-adjusted therapy in transplant non-eligible patients with newly diagnosed multiple myeloma (FiTNEss (UK-MRA Myeloma XIV Trial)): a study protocol for a randomised phase III trial. BMJ Open. 2022; 12(6):e056147.","DOI":"10.1136\/bmjopen-2021-056147"},{"key":"59975","doi-asserted-by":"crossref","unstructured":"Efficace F, Gaidano G, Petrucci MT. Association of IMWG frailty score with health-related quality of life profile of patients with relapsed refractory multiple myeloma in Italy and the UK: a GIMEMA, multicentre, cross-sectional study. Lancet Healthy Longev. 2022; 3(9):e628-e635.","DOI":"10.1016\/S2666-7568(22)00172-6"},{"key":"59976","doi-asserted-by":"crossref","unstructured":"Pawlyn C, Khan AM, Freeman CL. Fitness and frailty in myeloma. Hematol Am Soc Hematol Educ Program. 2022; 2022(1):337-348.","DOI":"10.1182\/hematology.2022000346"},{"key":"59977","doi-asserted-by":"crossref","unstructured":"Scheubeck S, Ihorst G, Schoeller K. Comparison of the prognostic significance of 5 comorbidity scores and 12 functional tests in a prospective multiple myeloma patient cohort. Cancer. 2021; 127(18):3422-3436.","DOI":"10.1002\/cncr.33658"},{"key":"59978","doi-asserted-by":"crossref","unstructured":"Facon T, Dimopoulos MA, Meuleman N. A simplified frailty scale predicts outcomes in transplant-ineligible patients with newly diagnosed multiple myeloma treated in the FIRST (MM-020) trial. Leukemia. 2020; 34(1):224-233.","DOI":"10.1038\/s41375-019-0539-0"},{"key":"59979","doi-asserted-by":"crossref","unstructured":"Palumbo A, Bringhen S, Mateos M-V. Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report. Blood. 2015; 125(13):2068-2074.","DOI":"10.1182\/blood-2014-12-615187"},{"key":"59980","doi-asserted-by":"crossref","unstructured":"Engelhardt M, Domm A-S, Dold SM. A concise revised Myeloma Comorbidity Index as a valid prognostic instrument in a large cohort of 801 multiple myeloma patients. Haematologica. 2017; 102(5):910-921.","DOI":"10.3324\/haematol.2016.162693"},{"key":"59981","doi-asserted-by":"crossref","unstructured":"Holler M, Ihorst G, Reinhardt H. An objective assessment in newly diagnosed multiple myeloma to avoid treatment complications and strengthen therapy adherence. Haematologica. 2023; 108(4):1115-1126.","DOI":"10.3324\/haematol.2022.281489"},{"key":"59982","doi-asserted-by":"crossref","unstructured":"Mian H, McCurdy A, Giri S. The prevalence and outcomes of frail older adults in clinical trials in multiple myeloma: a systematic review. Blood Cancer J. 2023; 13(1):1-13.","DOI":"10.1038\/s41408-022-00779-2"},{"key":"59983","doi-asserted-by":"crossref","unstructured":"Mateos M-V, Dimopoulos MA, Cavo M. Daratumumab plus bortezomib, melphalan, and prednisone versus bortezomib, melphalan, and prednisone in transplant-ineligible newly diagnosed multiple myeloma: frailty subgroup analysis of ALCYONE. Clin Lymphoma Myeloma Leuk. 2021; 21(11):785-798.","DOI":"10.1016\/j.clml.2021.06.005"},{"key":"59984","doi-asserted-by":"crossref","unstructured":"Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987; 40(5):373-383.","DOI":"10.1016\/0021-9681(87)90171-8"},{"key":"59985","doi-asserted-by":"crossref","unstructured":"Milani P, Vincent Rajkumar S, Merlini G. N-terminal fragment of the type-B natriuretic peptide (NT-proBNP) contributes to a simple new frailty score in patients with newly diagnosed multiple myeloma. Am J Hematol. 2016; 91(11):1129-1134.","DOI":"10.1002\/ajh.24532"},{"key":"59986","doi-asserted-by":"crossref","unstructured":"Cook G, Royle K-L, Pawlyn C. A clinical prediction model for outcome and therapy delivery in transplant-ineligible patients with myeloma (UK Myeloma Research Alliance Risk Profile): a development and validation study. Lancet Haematol. 2019; 6(3):e154.e166.","DOI":"10.1016\/S2352-3026(18)30220-5"},{"key":"59987","doi-asserted-by":"crossref","unstructured":"Eichhorst B, Hallek M, Goede V. Management of unfit elderly patients with chronic lymphocytic leukemia. Eur J Intern Med. 2018; 58:7-13.","DOI":"10.1016\/j.ejim.2018.02.001"},{"key":"59988","doi-asserted-by":"crossref","unstructured":"Auner HW, Brown SR, Walker K. Ixazomib with cyclophosphamide and dexamethasone in relapsed or refractory myeloma: MUKeight phase II randomised controlled trial results. Blood Cancer J. 2022; 12(4):52.","DOI":"10.1038\/s41408-022-00626-4"}],"container-title":["Haematologica"],"original-title":[],"link":[{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2023.283884\/76372","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2023.283884\/76816","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/11362\/76372","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:05:19Z","timestamp":1794045919000},"score":1,"resource":{"primary":{"URL":"https:\/\/haematologica.org\/article\/view\/haematol.2023.283884"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,30]]},"references-count":16,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2024,3,31]]}},"URL":"https:\/\/doi.org\/10.3324\/haematol.2023.283884","relation":{},"ISSN":["1592-8721","0390-6078"],"issn-type":[{"value":"1592-8721","type":"electronic"},{"value":"0390-6078","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11,30]]}}}